Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

Rheumatoid Arthritis

Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

BMJ Open

Rayner F, Hiu S, Melville A, Bigirumurame T, Anderson A, Dyke B, Kerrigan S, McGucken A, Prichard J, Shahrokhabadi MS, Hilkens CMU, Buckley CD, McInnes IB, Ng WF, Goodyear C, Teare D, Filer A, Siebert S, Raza K, Pratt A, Baker KF, Isaacs J

doi: 10.1136/bmjopen-2024-092478

Rheumatoid Arthritis

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

Rheumatology (Oxford)

Hiramatsu Y, Kotani T, Nakamura E, Yoshikawa A, Hashimoto M, Onishi A, Murata K, Yamamoto N, Murakami K, Hirano T, Maeda Y, Ebina K, Sendo S, Son Y, Amuro H, Hara R, Katayama M, Yamamoto W, Takeuchi T

doi: 10.1093/rheumatology/keaf558

Rheumatoid Arthritis

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm

Ann Rheum Dis

Hetland ML, Heiberg MS, Sokka-Isler T, Rudin A, Østergaard M, Haavardsholm E, Rutanen J, van Vollenhoven R, Grondal G, Ørnbjerg LM, Bøyesen P, Lampa J, Nurmohamed M, Gudbjornsson B, Uhlig T, Kononoff A, Lend K, Krabbe S, Olsen IC, Sexton J, Hørslev-Petersen K

doi: 10.1016/j.ard.2025.03.002

Rheumatoid Arthritis

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Rheumatol Ther

Taylor PC, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B, Alten R, Nash P, Feist E

doi: 10.1007/s40744-024-00732-8

Psoriatic Arthritis

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Ann Rheum Dis

Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A

doi: 10.1136/ard-2024-226150

Rheumatoid Arthritis

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence

J Rheumatol

Freites Núñez D, Gallego A, García Dorta A, García-Valle A, Valero Expósito M, De la Morena Barrio I, Arconada C, Valero C, Fernández-Prada M, López I Gómez M, Álvarez de Cienfuegos A, López-Sánchez R, García Martos Á

doi: 10.3899/jrheum.2025-0102

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Rheumatoid Arthritis

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study

J Rheumatol

Edwards CJ, Krönke G, Avouac J, Li Z, Conti F, Balsa A, Mo D, Haladyj E, Fischer P, Tanaka M, Takita Y, Hagimori K, Takeuchi T

doi: 10.3899/jrheum.2024-0906

Related content

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study